Xeris Biopharma Holdings, Inc. (LON:0A8E)
6.80
-0.18 (-2.51%)
Feb 12, 2026, 3:59 PM GMT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $74.38M USD in the quarter ending September 30, 2025, with 37.06% growth. This brings the company's revenue in the last twelve months to $266.14M, up 42.05% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$266.14M
Revenue Growth
+42.05%
P/S Ratio
4.24
Revenue / Employee
$675.47K
Employees
394
Market Cap
840.32M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
| Oxford Biomedica | 151.21M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |
Xeris Biopharma Holdings News
- 9 days ago - Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity - Seeking Alpha
- 4 weeks ago - XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Price Target | XERS Stock News - GuruFocus
- 5 weeks ago - Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
- 5 weeks ago - Xeris Biopharma expects full-year 2025 revenue above estimates - Seeking Alpha
- 5 weeks ago - Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - Business Wire
- 5 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - The Motley Fool
- 7 weeks ago - Director John Johnson Sells 135,400 Shares of Xeris Biopharma Holdings Inc - GuruFocus